cropped color_logo_with_background.png

Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma

Study Purpose

This study evaluates the safety associated with the addition of sulfasalazine to stereotactic radiosurgery for recurrent glioblastoma. Sulfasalazine is a potential tumor selective radiosensitizer.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Histologically verified glioblastoma multiforme with recurrence (first or second relapse, all subtypes) based on the Response Assessment in Neuro-Oncology criteria.
  • - Prior standard therapy for newly diagnosed glioblastoma consisting of surgery, standard fractionated radiotherapy to 60 Gy concomitant with Temozolomide.
  • - Has been informed of other treatment options.
  • - Must be eligible to gamma knife treatment.
  • - Tumor size ≤ 3 cm in diameter (≤ 15 cm3 ) on MRI dated no more than 30 days before SRS treatment.
  • - Must be at least 18 years of age.
  • - Must be ambulatory with a Karnofsky performance status of ≥ 70.
  • - Life expectancy > 12 weeks.
  • - Laboratory parameters for vital functions should be in the normal reference range.
Laboratory abnormalities that are not clinically significant are generally permitted, except for the following laboratory parameters, which must be within the ranges specified: Hematology: White blood cell count: ≥ 3.0 x 109/l, Platelet count:: ≥ 100 x 109/l, Hemoglobin: ≥ 100 g/l, Total bilirubin level: <1.5 times the upper limit of normal (ULN) (except in patients with Gilbert's Syndrome who must have a total bilirubin less than 51,3 µmol/L), alanine aminotransferase < 3 times the ULN, Creatinine < 1.5 times the ULN, Normal prothrombin time / international normalized ratio (PT INR) < 1.4, Absolute neutrophil count: ≥ 1 x109/L without the support of filgrastim.
  • - More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less.
Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specified in the eligibility criteria.
  • - Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to national/local regulations.

Exclusion Criteria:

  • - Allergy to sulfa drugs.
  • - Adverse reactions to salicylates.
  • - Known hypersensitivity to sulfasalazine, its metabolites or any of the excipients (Povidone; Maize starch; magnesium stearate; colloidal silicon dioxide) - Eligible to alternative standard treatments with temozolomide.
  • - Treatment with sulfasalazine after glioblastoma diagnosis.
  • - Participation in pharmacokinetic trial within 4 weeks.
  • - Participation in immunotherapy trial within 4 weeks.
  • - History of psychological symptoms affecting ability to consent to and/or fulfill the protocol.
  • - Other malignant diseases and multiple sclerosis.
  • - Pregnant or breast feeding patients.
  • - Porphyria.
  • - Kidney of liver deficiencies.
  • - Glucose-6-phosphate dehydrogenase deficiency.
  • - Severe allergy or bronchial asthma.
  • - History of erythema multiforme.
  • - Significant heart failure or renal failure.
  • - Intestinal or urinary obstruction.
  • - Any reason why, in the opinion of the investigator, the patient should not participate (e.g. not able to comply with study procedures).

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04205357
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Haukeland University Hospital
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Bente S Skeie
Principal Investigator Affiliation Haukeland University Hospial
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries Norway
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Glioma, Glioblastoma, Recurrent Glioblastoma
Additional Details

Glioblastoma is the most aggressive and most common type of primary brain cancer. Standard treatment at diagnosis is surgery followed by high dose radiation therapy and chemotherapy. Despite initial treatment nearly all patients will experience recurrence of the tumor with a dismal prognosis. There is no consensus on standard of care at recurrence. Reoperation is associated with a high risk of complications and further conventional radiation therapy is often not possible as the maximum tolerated dose to the normal brain has already been given. In addition most tumors have developed resistance towards chemotherapy. Stereotactic radiosurgery (SRS) may be administered despite prior initial radiation treatment but in order to avoid radiation induced complications only limited doses to limited tumor volumes can be applied. Developing new strategies to improve the effect of radiation selectively on tumor cells without simultaneously increase the radiation induced damage of normal brain would be valuable. The investigators have shown in experimental studies that the drug sulfasalazine enhances the number of cancer cells that dies as result of radiation therapy and thereby improves survival in combination with SRS in animals with glioblastoma. Sulfasalazine inhibits the production of an antioxidant that normally protects the tumor against radiation. Hopefully the trial will result in a new and more effective treatment option for patients with recurrent glioblastoma.

Arms & Interventions

Arms

Other: Sulfasalazine in addition to stereotactic radiosurgery

3 + 3 dose escalation The first cohort of 3-6 patients will receive 1.5 g Sulfasalazine daily for 3 days before single fraction stereotactic radiosurgery utilizing 12 Gy prescription dose to the tumor margin. The second, third and fourth cohort will receive 3 days pretreatment with 3 g, 4.5 g and 6 g Sulfasalazine, respectively, before 12 Gy single fraction stereotactic radiosurgery.

Interventions

Drug: - Sulfasalazine

Sulfasalazine combined with stereotactic radiosurgery

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Haukeland University Hospital, Bergen, Norway

Status

Recruiting

Address

Haukeland University Hospital

Bergen, , 5021

Site Contact

Bente S Skeie, MD, PhD

bsai@helse-bergen.no

+47 55 97 5000